BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 17204403)

  • 1. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
    Vouillamoz J; Moreillon P; Giddey M; Entenza JM
    J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey.
    Arslan H; Azap OK; Ergin F; Karaman SO; Oruç E
    Int J Antimicrob Agents; 2004 Jun; 23(6):642-3. PubMed ID: 15194140
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
    Allen GP; Bierman BC
    Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Dandekar PK; Tessier PR; Williams P; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2003 Sep; 52(3):405-11. PubMed ID: 12917254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
    Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
    APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
    Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
    Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
    Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
    Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.